Dexmedetomidine reduces long-term potentiation in mouse hippocampus

Anesthesiology

Volumn 108, Issue 1, 2008, Pages 94-102

  Takamatsu, Isao ^a,b   Iwase, Ayano ^c,d   Ozaki, Makoto ^c   Kazama, Tomiei ^e   Wada, Keiji ^d   Sekiguchi, Masayuki ^d  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^d National Institute of Neuroscience

^e National Defense Medical College Research Institute

Author keywords

[No Author keywords available]

Indexed keywords

2 (4,5 DIHYDROIMIDAZ 2 YL) QUINOLINE; 2 BENZOFURANYL 2 IMIDALOLINE; DEXMEDETOMIDINE; EFAROXAN; IDAZOXAN; IMIDAZOLINE RECEPTOR; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PICROTOXIN; PRAZOSIN; UNCLASSIFIED DRUG; YOHIMBINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; LONG TERM POTENTIATION; MALE; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; SYNAPTIC POTENTIAL; SYNAPTIC TRANSMISSION;

EID: 37549020712     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/01.anes.0000296076.04510.e1     Document Type: Article

References (47)

1. Virtanen R, Savola JM, Saano V, Nyman L: Characterization of the selectivity, specificity and potency of medetomidine as an alpha 2-adrenoceptor agonist. Eur J Pharmacol 1988; 150:9-14
2. Sirvio J, Riekkinen P Jr, Ekonsalo T, Lammintausta R, Riekkinen PJ: The effects of dexmedetomidine, an alpha 2 agonist, on learning and memory, assessed using passive avoidance and water maze tasks in rats. Neuropharmacology 1992; 31:163-8
3. Haapalinna A, MacDonald E, Viitamaa T, Salonen JS, Sirvio J, Virtanen R: Comparison of the effects of acute and subchronic administration of atipamezole on reaction to novelty and active avoidance learning in rats. Naunyn Schmiedebergs Arch Pharmacol 1999; 359:194-203
4. Sara SJ, Devauges V: Idazoxan, an alpha-2 antagonist, facilitates memory retrieval in the rat. Behav Neural Biol 1989; 51:401-11
5. Bliss TV, Collingridge GL: A synaptic model of memory: Long-term potentiation in the hippocampus. Nature 1993; 361:31-9
6. DeBock F, Kurz J, Azad SC, Parsons CG, Hapfelmeier G, Zieglgansberger W, Rammes G: Alpha2-adrenoreceptor activation inhibits LTP and LTD in the basolateral amygdala: involvement of Gi/o-protein-mediated modulation of Ca2+-channels and inwardly rectifying K+-channels in LTD. Eur J Neurosci 2003; 17:1411-24
7. Niittykoski M, Haapalinna A, Sirvio J: Diminution of N-methyl-D- aspartate-induced perturbation of neurotransmission by dexmedetomidine in the CA1 field of rat hippocampus in vitro. Neurosci Lett 2000; 281:95-8
8. Saunders C, Limbird LE: Localization and trafficking of alpha2-adrenergic receptor subtypes in cells and tissues. Pharmacol Ther 1999; 84:193-205
9. Kable JW, Murrin LC, Bylund DB: In vivo gene modification elucidates subtype-specific functions of alpha(2)-adrenergic receptors. J Pharmacol Exp Ther 2000; 293:1-7
10. Starke K: Presynaptic autoreceptors in the third decade: focus on alpha2-adrenoceptors. J Neurochem 2001; 78:685-93
11. Yang HW, Lin YW, Yen CD, Min MY: Change in bi-directional plasticity at CA1 synapses in hippocampal slices taken from 6-hydroxydopamine-treated rats: the role of endogenous norepinephrine. Eur J Neurosci 2002; 16:1117-28
12. Wikberg JE, Uhlen S, Chhajlani V: Medetomidine stereoisomers delineate two closely related subtypes of idazoxan (imidazoline) I-receptors in the guinea pig. Eur J Pharmacol 1991; 193:335-40
13. Savola MK, Savola JM: [3H]dexmedetomidine, an alpha 2-adrenoceptor agonist, detects a novel imidazole binding site in adult rat spinal cord. Eur J Pharmacol 1996; 306:315-23
14. Regunathan S, Feinstein DL, Reis DJ: Expression of non-adrenergic imidazoline sites in rat cerebral cortical astrocytes. J Neurosci Res 1993; 34:681-8
15. Ruggiero DA, Regunathan S, Wang H, Milner TA, Reis DJ: Immunocytochemical localization of an imidazoline receptor protein in the central nervous system. Brain Res 1998; 780:270-93
16. Renouard A, Widdowson PS, Cordi A: [3H]-idazoxan binding to rabbit cerebral cortex recognises multiple imidazoline I2-type receptors: pharmacological characterization and relationship to monoamine oxidase. Br J Pharmacol 1993; 109:625-31
17. Takamatsu I, Sekiguchi M, Wada K, Sato T, Ozaki M: Propofol-mediated impairment of CA1 long-term potentiation in mouse hippocampal slices. Neurosci Lett 2005; 389:129-32
18. Zushida K, Sakurai M, Wada K, Sekiguchi M: Facilitation of extinction learning for contextual fear memory by PEPA: A potentiator of AMPA receptors. J Neurosci 2007; 27:158-66
19. Simon W, Hapfelmeier G, Kochs E, Zieglgansberger W, Rammes G: Isoflurane blocks synaptic plasticity in the mouse hippocampus. ANESTHESIOLOGY 2001; 94:1058-65
20. Bland BH: The physiology and pharmacology of hippocampal formation theta rhythms. Prog Neurobiol 1986; 26:1-54
21. Otto T, Eichenbaum H, Wiener SI, Wible CG: Learning-related patterns of CA1 spike trains parallel stimulation parameters optimal for inducing hippocampal long-term potentiation. Hippocampus 1991; 1:181-92
22. Staubli U, Lynch G: Stable hippocampal long-term potentiation elicited by 'theta' pattern stimulation. Brain Res 1987; 435:227-34
23. Nguyen PV, Duffy SN, Young JZ: Differential maintenance and frequency-dependent tuning of LTP at hippocampal synapses of specific strains of inbred mice. J Neurophysiol 2000; 84:2484-93
24. Rouot B, Quennedey MC, Schwartz J: Characteristics of the [3H]-yohimbine binding on rat brain alpha2-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 1982; 321:253-9
25. Broderick PA: Alprazolam, diazepam, yohimbine, clonidine: In vivo CA1 hippocampal norepinephrine and serotonin release profiles under chloral hydrate anesthesia. Prog Neuropsychopharmacol Biol Psychiatry 1997; 21:1117-40
26. Otmakhova NA, Lewey J, Asrican B, Lisman JE: Inhibition of perforant path input to the CA1 region by serotonin and noradrenaline. J Neurophysiol 2005; 94:1413-22
27. Bour S, Iglesias-Osma MC, Marti L, Duro P, Garcia-Barrado MJ, Pastor MF, Prevot D, Visentin V, Valet P, Moratinos J, Carpene C: The imidazoline I2-site ligands BU 224 and 2-BFI inhibit MAO-A and MAO-B activities, hydrogen peroxide production, and lipolysis in rodent and human adipocytes. Eur J Pharmacol 2006; 552:20-30
28. Izumi Y, Clifford DB, Zorumski CF: Norepinephrine reverses N-methyl-D-aspartate-mediated inhibition of long-term potentiation in rat hippocampal slices. Neurosci Lett 1992; 142:163-6
29. Paulsen O, Moser EI: A model of hippocampal memory encoding and retrieval: GABAergic control of synaptic plasticity. Trends Neurosci 1998; 21:273-8
30. Pittaluga A, Raiteri M: GABAergic nerve terminals in rat hippocampus possess alpha 2-adrenoceptors regulating GABA release. Neurosci Lett 1987; 76:363-7
31. Maura G, Pittaluga A, Ulivi M, Raiteri M: Enhancement of endogenous GABA release from rat synaptosomal preparations is mediated by alpha 2-adrenoceptors pharmacologically different from alpha 2-autoreceptors. Eur J Pharmacol 1988; 157:23-9
32. Zucker RS, Regehr WG: Short-term synaptic plasticity. Annu Rev Physiol 2002; 64:355-405
33. Nicoll RA, Malenka RC: Expression mechanisms underlying NMDA receptor-dependent long-term potentiation. Ann N Y Acad Sci 1999; 868:515-25
34. Nicoll RA: Expression mechanisms underlying long-term potentiation: A postsynaptic view. Philos Trans R Soc Lond B Biol Sci 2003; 358:721-6
35. Nguyen PV, Abel T, Kandel ER: Requirement of a critical period of transcription for induction of a late phase of LTP. Science 1994; 265:1104-7
36. Gelinas JN, Nguyen PV: Beta-adrenergic receptor activation facilitates induction of a protein synthesis-dependent late phase of long-term potentiation. J Neurosci 2005; 25:3294-303
37. Mondaca M, Hernandez A, Perez H, Valladares L, Sierralta W, Fernandez V, Soto-Moyano R,: Alpha2-adrenoceptor modulation of long-term potentiation elicited in vivo in rat occipital cortex. Brain Res 2004; 1021:292-6
38. Ge YX, Xin WJ, Hu NW, Zhang T, Xu JT, Liu XG: Clonidine depresses LTP of C-fiber evoked field potentials in spinal dorsal horn via NO-cGMP pathway. Brain Res 2006; 1118:58-65
39. Takada K, Hayashi Y, Kamibayashi T, Mammoto T, Yamatodani A, Kitamura S, Yoshiya I: The involvement of pertussis toxin-sensitive G proteins in the post receptor mechanism of central I1-imidazoline receptors. Br J Pharmacol 1997; 120:1575-81
40. Eglen RM, Hudson AL, Kendall DA, Nutt DJ, Morgan NG, Wilson VG, Dillon MP: "Seeing through a glass darkly": Casting light on imidazoline "I" sites. Trends Pharmacol Sci 1998; 19:381-90
41. Sanchez-Blazquez P, Boronat MA, Olmos G, Garcia-Sevilla JA, Garzon J: Activation of I(2)-imidazoline receptors enhances supraspinal morphine analgesia in mice: A model to detect agonist and antagonist activities at these receptors. Br J Pharmacol 2000; 130:146-52
42. Sastre-Coll A, Esteban S, Garcia-Sevilla JA,: Effects of 2-(2-benzofuranyl)-2-imidazoline (2-BFI) on dopamine synthesis in rat striatum in vivo. Ann N Y Acad Sci 1999; 881:364
43. Esteban S, Sastre-Coll A, Garcia-Sevilla JA,: Effects of imidazoline drugs on tyrosine and tryptophan hydroxylase activity in rat brain in vivo. Ann N Y Acad Sci 1999; 881:358
44. Tesson F, Parini A: Identification of an imidazoline-guanidinium receptive site in mitochondria from rabbit cerebral cortex. Eur J Pharmacol 1991; 208:81-3
45. Parini A, Moudanos CG, Pizzinat N, Lanier SM: The elusive family of imidazoline binding sites. Trends Pharmacol Sci 1996; 17:13-6
46. Lopes da Silva FH, Witter MP, Boeijinga PH, Lohman AH: Anatomic organization and physiology of the limbic cortex. Physiol Rev 1990; 70:453-511
47. Nutt DJ, Lalies MD, Lione LA, Hudson AL: Noradrenergic mechanisms in the prefrontal cortex. J Psychopharmacol 1997; 11:163-8